Viral Inception of Asthma: Prospective Study From Infancy to School-age
NCT ID: NCT00731575
Last Updated: 2011-08-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
200 participants
Study Classification
INTERVENTIONAL
Study Start Date
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to study prospectively the early clinical and immunological events in children susceptible to rhinovirus induced early wheezing (i.e., recently found highest risk factor for recurrent wheezing/asthma) and the efficacy of systemic corticosteroid to modify these events.
Up to 50% of children suffer from acute wheezing before school-age. The prevalence of childhood asthma is 5-7%. Although pediatric asthma is mainly allergic, the exacerbations are associated with respiratory viral infections in 95% of cases. The means to predict asthma from environmental factors have been limited mainly to sensitization to aeroallergens (3-fold risk), which start to develop usually at 2-3 years of age. VINKU 1-study (orig. VINKU-study) discovered simultaneously with two other groups, that early wheezing associated with rhinovirus, the "common cold" virus, is the strongest predictor of recurrent wheezing/asthma (up to 10-fold risky). Noteworthily, viral infections work as risk markers already during infancy, a lot earlier than the sensitization to aeroallergens. The investigators also found retrospectively that early wheezers affected by rhinovirus responded to 3 day course of oral prednisolone (inexpensive and widely available treatment): recurrent wheezing decreased by 50% during following 12 months and the difference appeared to continue. VINKU 5V-study is currently investigating the clinical history, prevalence of asthma and airway hyperreactivity of these same children at school-age. The mechanism of rhinovirus associated risk or why they respond to prednisolone are largely unknown. However, the susceptibility to rhinovirus infections is associated with atopy and therefore it is possible these children may have impaired anti-inflammatory (Treg) responses and more likely to wheeze with any pro-inflammatory response (Th1 or Th2). Moreover, they may not effectively clear viruses, because they can not limit rhinovirus to nose and it spreads to lower airways and causes wheezing. VINKU 2-study will prospectively investigate the immunological events in young first-time wheezers affected by rhinovirus, and prospectively study the clinical efficacy of systemic corticosteroid in them. Most likely these children will benefit from the drug in terms of less recurrent wheezing, the investigators will also explore immunological effects of the drug and their link to clinical efficacy. The results are expected to give basis for the prevention of asthma and for the development of new treatment strategies and they can be directly applied to clinical medicine.
Up to 50% of children suffer from acute wheezing before school-age. The prevalence of childhood asthma is 5-7%. Although pediatric asthma is mainly allergic, the exacerbations are associated with respiratory viral infections in 95% of cases. The means to predict asthma from environmental factors have been limited mainly to sensitization to aeroallergens (3-fold risk), which start to develop usually at 2-3 years of age. VINKU 1-study (orig. VINKU-study) discovered simultaneously with two other groups, that early wheezing associated with rhinovirus, the "common cold" virus, is the strongest predictor of recurrent wheezing/asthma (up to 10-fold risky). Noteworthily, viral infections work as risk markers already during infancy, a lot earlier than the sensitization to aeroallergens. The investigators also found retrospectively that early wheezers affected by rhinovirus responded to 3 day course of oral prednisolone (inexpensive and widely available treatment): recurrent wheezing decreased by 50% during following 12 months and the difference appeared to continue. VINKU 5V-study is currently investigating the clinical history, prevalence of asthma and airway hyperreactivity of these same children at school-age. The mechanism of rhinovirus associated risk or why they respond to prednisolone are largely unknown. However, the susceptibility to rhinovirus infections is associated with atopy and therefore it is possible these children may have impaired anti-inflammatory (Treg) responses and more likely to wheeze with any pro-inflammatory response (Th1 or Th2). Moreover, they may not effectively clear viruses, because they can not limit rhinovirus to nose and it spreads to lower airways and causes wheezing. VINKU 2-study will prospectively investigate the immunological events in young first-time wheezers affected by rhinovirus, and prospectively study the clinical efficacy of systemic corticosteroid in them. Most likely these children will benefit from the drug in terms of less recurrent wheezing, the investigators will also explore immunological effects of the drug and their link to clinical efficacy. The results are expected to give basis for the prevention of asthma and for the development of new treatment strategies and they can be directly applied to clinical medicine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Video Assisted Study of Salbutamol Response in Viral Wheezing
NCT06093152
Wheezing
RECRUITING
The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children
NCT02743663
Asthma
Wheeze
Obstructive Sleep Apnea
+2 more
COMPLETED
Determinants Of Oral Corticosteroid Responsiveness in Wheezing Asthmatic Youth
NCT02013076
Asthma
COMPLETED
Clinical Trial of Fluticasone Versus Placebo at the Onset of a Cold for Children With Asthma
NCT00238927
Asthma
COMPLETED
PHASE4
Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children
NCT00515775
Allergic Asthma
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Main Hypothesis and Anticipated Results
Virology
1. Rhinovirus is a common causative agent of bronchiolitis.
2. Persistence of rhinovirus (or any virus) infection worsens long-term outcome.
3. The dose of virus inoculation at the time of acute wheezing (assessed semi-quantitatively for rhinovirus and respiratory syncytial virus) is related to outcome.
Immunology
4. Children susceptible to rhinovirus induced early wheezing have altered immunology (T cell regulation and interferon responses) when compared to children with RSV induced wheezing and children with rhinovirus induced upper respiratory infection without wheezing.
5. These immunological events are related to recurrent wheezing and asthma inception.
Therapeutic intervention with systemic corticosteroid
Systemic corticosteroid in children susceptible for rhinovirus-induced early wheezing
6. decreases persistence of rhinovirus infection
7. decreases the severity and relapses of the first wheezing episode, and prevents recurrent wheezing, and asthma,
8. prevents Th2-polarization, favours Th1- and Treg-responses during the treatment period.
Design and Time
Prospective, randomized, double blind, placebo controlled, parallel, one-center trial. The study was commenced in 6/2007.
Inclusion Criteria
Age 3-23 months, be delivered at \>37 weeks, first wheezing episode, written informed consent from guardian.
Inclusion Criteria for the Intervention and the Follow-up
Rhinovirus PCR positive wheezing episode and still signs of lower respiratory symptoms (cough, noisy breathing or wheezing) at the time the initiation of study drug.
Inclusion Criteria for the Follow-up without Intervention
Any rhinovirus negative wheezing episode.
Exclusion Criteria
Chronic illness other than atopy, previous systemic or inhaled corticosteroid treatment, participation to another study (excluding long-term follow-up studies in childhood), varicella contact if previously intact, need for intensive care unit treatment, or poor understanding of Finnish.
Intervention
The need for hospitalization will be decided independently of the study by an on-duty physician in the emergency room. Whether hospitalized or not, the eligible children (rhinovirus positive wheezers, n=70) will be randomly assigned (2 separate randomization lists: one for hospitalized and one for out-patients) in a double-blind fashion to receive either oral prednisolone (first dose 2 mg/kg (max 60 mg), then 2 mg/kg/d (max 60 mg/d) in 3 divided doses for 3 days, Prednisolon®, 5 mg tablets, Oy Leiras Finland Ab, Helsinki, Finland) or placebo after informed consent had been obtained. The randomization code list will be stored in the hospital pharmacy and will be revealed only after all children had completed first 2 months of the study. Separate codes for each patients will be stored in patients charts and revealed in case of emergency. The tablets and packages will be indistinguishable in appearance from those of the active drug (Oy Leiras Finland Ab, Helsinki, Finland) and be provided in numbered containers. The study drugs will be administered by nurses independent of the study or by parents. The tablets will be minced and administered with jelly or yogurt. All patients will receive nebulized albuterol 0.15 mg/kg at 2 h intervals for the first 12 h, then at 4 h intervals while in the hospital. After discharge, beta2-agonists were used on demand. The patients will receive antibiotics or nebulized epinephrine (in emergency room or hospital) on demand.
Risk-benefit ratio
Previously, the efficacy of prednisolone has only been evaluated post-hoc in rhinovirus induced early wheezing in \<3 year-old-children. The prevalence of relapses within 2 months after discharge was 22% in prednisolone group and 56% in placebo group. This observation needs to be confirmed in a prospective randomized trial, which is the purpose of the current study. Prednisolone has not been found beneficial in RSV-induced early wheezing in many studies and therefore, is not recommended to these children. Neither, prednisolone is used in upper respiratory tract infections without wheezing. Short courses (up to 5 days) of prednisolone have been used for decades in the treatment wheezing illnesses and they are well tolerated. There are no data that this dosage in this patient group could cause similar long-term neurological consequences as systemic corticosteroid treatment in mechanically ventilated premature infants suffering from severe respiratory distress syndrome.
Sample Size
Required sample size for the intervention will be \>70 rhinovirus positive wheezing patients, which will include \>35 infants for prednisolone group and \>35 infants for placebo group. In addition, \>200 healthy control children (no wheezing during the first 2 years of life) will be recruited and followed until school age.
Our primary endpoint is the occurrence of new wheezing episode within 2 months after discharge. According to our previous data on rhinovirus induced first or second episode of wheezing in children aged less than 3 years, the prevalence of relapses within 2 months after discharge in prednisolone group is 22% and in placebo group 56%. To maintain an alpha error of 0.05 and a beta error of 0.20, the required size of the sample is 29 children for each treatment group for the 2-month follow-up. When assessing the risk for the development of asthma at age 6 years, we expect 60% in the rhinovirus group and 18% in the RSV group to develop asthma by that age. We expect approximately 10-20% of the children to discontinue the study within 6 years. Thus, 35 children are needed in each group for the follow-up until school-age.
We expect approximately 15-25 subjects in each virus specific group to be sufficient to reveal immunologically or clinically meaningful differences.
Recruitment
Study subject will be recruited in the outpatient clinic of the Department of Pediatrics, or in the Pediatric Infectious Diseases Ward in the Turku University Hospital. Study physician/nurse or on-duty physician/nurse tells the guardian about the study and givens written information about the study. After the guardian has had adequate time the get familiar with the study and has had change to ask, his/her signature will be seeked to the informed consent form and the study will commence.
Description of Laboratory Methods for VINKU 2-study
The study protocol is presented in Table 1. Several laboratory analyses will enable us to address questions regarding the relationship between viral infections, T cell regulation, genetics, atopy, and pulmonary function. Laboratory work will be done according to modern standards.
Outcomes of the Intervention
Primary outcome: The occurrence of and time to a new physician-confirmed wheezing episode within 2 months after discharge; number of physician-confirmed wheezing episodes during the first 12 months after discharge; diagnoses of asthma during the full study period. Asthma is defined according to NAEPP Guidelines (http://www.nhlbi.nih.gov/guidelines/asthma).
Secondary outcomes: Up to 2 weeks after the acute respiratory tract infection, severity of symptoms (cough, wheeze, noisy breathing, breathlessness, rhinitis) will be assessed on a 4-graded scale (0-3, mild 1, moderate 2 and severe 3) by the parents as well as exact number of bronchodilator puffs used (symptom diary 1). Up to 2 months after the acute respiratory tract infection, parents will record days with rhinitis, cough, noisy breathing, wheezing, night-time symptoms, medication (bronchodilator, corticosteroid or antibiotics) and visits to physician or hospitalizations for wheezing (symptom diary 2). Up to 12 months, the number of out-patient care visits and hospitalizations for wheezing and courses of systemic or inhaled corticosteroids will be recorded (diary 3). Multiple immunologic markers and pulmonary function after 24-36 months and at age 6 years will be measured.
Termination of Study
Criteria for the termination of the study are:
1. Parent or guardian neglects the study orders.
2. Parent or guardian does not want to continue the study with any reason.
3. Completion of the study.
Ethical Aspects
The study protocol has been approved by the Ethics Committee of the Turku University Hospital in 11/2006 and will follow the rules of the current revision of the Declaration of Helsinki and the directives for clinical research by European Union (HE 20/2004). Patients or guardian won't get any financial benefits from the study. Children will be covered by the insurance (potilasvakuutus). This is an academic project and researchers have no conflicts of interests. Patient data will be confidential and won't be shared outside research group without coding. All deviations from the original protocol will be reported to the Ethics Committee of the Turku University Hospital and to the national authorities (Lääkelaitos).
Adverse events
All adverse events during hospitalization will be recorded on a four-point scale (0-3) and their possible relation to study drug will be assessed on a three-point scale (no, possible, likely, Appendix 4). Parents will be asked to record all adverse events on a two-week home symptom diary (Appendix 5). Investigator shall report all clinically meaningful adverse events in a timely correct manner to the national authorities (Lääkelaitos) according to national law, and to Leiras / Drug Safety Officer Johanna Kause. In case of premature termination of the trial, due to safety concerns, the investigator shall write a safety summary report and immediately forward this to Leiras and the national authorities. In case of an emergency, sealed envelope containing the randomization code will be available in the patient chart in the Turku University Hospital and can be easily opened.
Virology
1. Rhinovirus is a common causative agent of bronchiolitis.
2. Persistence of rhinovirus (or any virus) infection worsens long-term outcome.
3. The dose of virus inoculation at the time of acute wheezing (assessed semi-quantitatively for rhinovirus and respiratory syncytial virus) is related to outcome.
Immunology
4. Children susceptible to rhinovirus induced early wheezing have altered immunology (T cell regulation and interferon responses) when compared to children with RSV induced wheezing and children with rhinovirus induced upper respiratory infection without wheezing.
5. These immunological events are related to recurrent wheezing and asthma inception.
Therapeutic intervention with systemic corticosteroid
Systemic corticosteroid in children susceptible for rhinovirus-induced early wheezing
6. decreases persistence of rhinovirus infection
7. decreases the severity and relapses of the first wheezing episode, and prevents recurrent wheezing, and asthma,
8. prevents Th2-polarization, favours Th1- and Treg-responses during the treatment period.
Design and Time
Prospective, randomized, double blind, placebo controlled, parallel, one-center trial. The study was commenced in 6/2007.
Inclusion Criteria
Age 3-23 months, be delivered at \>37 weeks, first wheezing episode, written informed consent from guardian.
Inclusion Criteria for the Intervention and the Follow-up
Rhinovirus PCR positive wheezing episode and still signs of lower respiratory symptoms (cough, noisy breathing or wheezing) at the time the initiation of study drug.
Inclusion Criteria for the Follow-up without Intervention
Any rhinovirus negative wheezing episode.
Exclusion Criteria
Chronic illness other than atopy, previous systemic or inhaled corticosteroid treatment, participation to another study (excluding long-term follow-up studies in childhood), varicella contact if previously intact, need for intensive care unit treatment, or poor understanding of Finnish.
Intervention
The need for hospitalization will be decided independently of the study by an on-duty physician in the emergency room. Whether hospitalized or not, the eligible children (rhinovirus positive wheezers, n=70) will be randomly assigned (2 separate randomization lists: one for hospitalized and one for out-patients) in a double-blind fashion to receive either oral prednisolone (first dose 2 mg/kg (max 60 mg), then 2 mg/kg/d (max 60 mg/d) in 3 divided doses for 3 days, Prednisolon®, 5 mg tablets, Oy Leiras Finland Ab, Helsinki, Finland) or placebo after informed consent had been obtained. The randomization code list will be stored in the hospital pharmacy and will be revealed only after all children had completed first 2 months of the study. Separate codes for each patients will be stored in patients charts and revealed in case of emergency. The tablets and packages will be indistinguishable in appearance from those of the active drug (Oy Leiras Finland Ab, Helsinki, Finland) and be provided in numbered containers. The study drugs will be administered by nurses independent of the study or by parents. The tablets will be minced and administered with jelly or yogurt. All patients will receive nebulized albuterol 0.15 mg/kg at 2 h intervals for the first 12 h, then at 4 h intervals while in the hospital. After discharge, beta2-agonists were used on demand. The patients will receive antibiotics or nebulized epinephrine (in emergency room or hospital) on demand.
Risk-benefit ratio
Previously, the efficacy of prednisolone has only been evaluated post-hoc in rhinovirus induced early wheezing in \<3 year-old-children. The prevalence of relapses within 2 months after discharge was 22% in prednisolone group and 56% in placebo group. This observation needs to be confirmed in a prospective randomized trial, which is the purpose of the current study. Prednisolone has not been found beneficial in RSV-induced early wheezing in many studies and therefore, is not recommended to these children. Neither, prednisolone is used in upper respiratory tract infections without wheezing. Short courses (up to 5 days) of prednisolone have been used for decades in the treatment wheezing illnesses and they are well tolerated. There are no data that this dosage in this patient group could cause similar long-term neurological consequences as systemic corticosteroid treatment in mechanically ventilated premature infants suffering from severe respiratory distress syndrome.
Sample Size
Required sample size for the intervention will be \>70 rhinovirus positive wheezing patients, which will include \>35 infants for prednisolone group and \>35 infants for placebo group. In addition, \>200 healthy control children (no wheezing during the first 2 years of life) will be recruited and followed until school age.
Our primary endpoint is the occurrence of new wheezing episode within 2 months after discharge. According to our previous data on rhinovirus induced first or second episode of wheezing in children aged less than 3 years, the prevalence of relapses within 2 months after discharge in prednisolone group is 22% and in placebo group 56%. To maintain an alpha error of 0.05 and a beta error of 0.20, the required size of the sample is 29 children for each treatment group for the 2-month follow-up. When assessing the risk for the development of asthma at age 6 years, we expect 60% in the rhinovirus group and 18% in the RSV group to develop asthma by that age. We expect approximately 10-20% of the children to discontinue the study within 6 years. Thus, 35 children are needed in each group for the follow-up until school-age.
We expect approximately 15-25 subjects in each virus specific group to be sufficient to reveal immunologically or clinically meaningful differences.
Recruitment
Study subject will be recruited in the outpatient clinic of the Department of Pediatrics, or in the Pediatric Infectious Diseases Ward in the Turku University Hospital. Study physician/nurse or on-duty physician/nurse tells the guardian about the study and givens written information about the study. After the guardian has had adequate time the get familiar with the study and has had change to ask, his/her signature will be seeked to the informed consent form and the study will commence.
Description of Laboratory Methods for VINKU 2-study
The study protocol is presented in Table 1. Several laboratory analyses will enable us to address questions regarding the relationship between viral infections, T cell regulation, genetics, atopy, and pulmonary function. Laboratory work will be done according to modern standards.
Outcomes of the Intervention
Primary outcome: The occurrence of and time to a new physician-confirmed wheezing episode within 2 months after discharge; number of physician-confirmed wheezing episodes during the first 12 months after discharge; diagnoses of asthma during the full study period. Asthma is defined according to NAEPP Guidelines (http://www.nhlbi.nih.gov/guidelines/asthma).
Secondary outcomes: Up to 2 weeks after the acute respiratory tract infection, severity of symptoms (cough, wheeze, noisy breathing, breathlessness, rhinitis) will be assessed on a 4-graded scale (0-3, mild 1, moderate 2 and severe 3) by the parents as well as exact number of bronchodilator puffs used (symptom diary 1). Up to 2 months after the acute respiratory tract infection, parents will record days with rhinitis, cough, noisy breathing, wheezing, night-time symptoms, medication (bronchodilator, corticosteroid or antibiotics) and visits to physician or hospitalizations for wheezing (symptom diary 2). Up to 12 months, the number of out-patient care visits and hospitalizations for wheezing and courses of systemic or inhaled corticosteroids will be recorded (diary 3). Multiple immunologic markers and pulmonary function after 24-36 months and at age 6 years will be measured.
Termination of Study
Criteria for the termination of the study are:
1. Parent or guardian neglects the study orders.
2. Parent or guardian does not want to continue the study with any reason.
3. Completion of the study.
Ethical Aspects
The study protocol has been approved by the Ethics Committee of the Turku University Hospital in 11/2006 and will follow the rules of the current revision of the Declaration of Helsinki and the directives for clinical research by European Union (HE 20/2004). Patients or guardian won't get any financial benefits from the study. Children will be covered by the insurance (potilasvakuutus). This is an academic project and researchers have no conflicts of interests. Patient data will be confidential and won't be shared outside research group without coding. All deviations from the original protocol will be reported to the Ethics Committee of the Turku University Hospital and to the national authorities (Lääkelaitos).
Adverse events
All adverse events during hospitalization will be recorded on a four-point scale (0-3) and their possible relation to study drug will be assessed on a three-point scale (no, possible, likely, Appendix 4). Parents will be asked to record all adverse events on a two-week home symptom diary (Appendix 5). Investigator shall report all clinically meaningful adverse events in a timely correct manner to the national authorities (Lääkelaitos) according to national law, and to Leiras / Drug Safety Officer Johanna Kause. In case of premature termination of the trial, due to safety concerns, the investigator shall write a safety summary report and immediately forward this to Leiras and the national authorities. In case of an emergency, sealed envelope containing the randomization code will be available in the patient chart in the Turku University Hospital and can be easily opened.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Asthma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
prednisolone
First dose 2 mg/kg (max 60 mg) p.o., then 2 mg/kg/d (max 60 mg/d) p.o. in 3 divided doses for 3 days.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Prednisolon®, 5 mg tablets, Oy Leiras Finland Ab, Helsinki, Finland.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 3-23 months
* be delivered at \>=37 weeks
* first wheezing episode
* written informed consent from guardian
* be delivered at \>=37 weeks
* first wheezing episode
* written informed consent from guardian
Exclusion Criteria
* chronic illness other than atopy
* previous systemic or inhaled corticosteroid treatment
* participation to another study
* varicella contact if previously intact
* need for intensive care unit treatment, or
* poor understanding of Finnish
* previous systemic or inhaled corticosteroid treatment
* participation to another study
* varicella contact if previously intact
* need for intensive care unit treatment, or
* poor understanding of Finnish
Minimum Eligible Age
3 Months
Maximum Eligible Age
24 Months
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cultural Foundation of Finland, Helsinki, Finland
UNKNOWN
Sponsor Role
collaborator
Maud Kuistila Foundation, Helsinki, Finland
UNKNOWN
Sponsor Role
collaborator
Foundation for Paediatric Research, Finland
OTHER
Sponsor Role
collaborator
Foundation for outpatient Research, Helsinki, Finland
UNKNOWN
Sponsor Role
collaborator
Turku University Hospital
OTHER_GOV
Sponsor Role
collaborator
The Paulo Foundation
OTHER
Sponsor Role
collaborator
Juselius Foundation, Helsinki, Finland
UNKNOWN
Sponsor Role
collaborator
University of Turku
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dept of Pediatrics, Turku University Hospital, Turku, Finland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept of Pediatrics, Turku University Hospital
Turku, , Finland
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Finland
References
Explore related publications, articles, or registry entries linked to this study.
Forsstrom V, Toivonen L, Homil K, Waris M, Pedersen CT, Bonnelykke K, Jartti T, Peltola V. Association of Asthma Risk Alleles With Acute Respiratory Tract Infections and Wheezing Illnesses in Young Children. J Infect Dis. 2023 Oct 18;228(8):990-998. doi: 10.1093/infdis/jiad075.
Reference Type
DERIVED
Erkkola RA, Virta LJ, Vahlberg T, Jartti T. Prednisolone for the first rhinovirus induced wheezing reduces use of respiratory medication. Pediatr Allergy Immunol. 2022 Jan;33(1):e13668. doi: 10.1111/pai.13668. Epub 2021 Sep 29. No abstract available.
Reference Type
DERIVED
Hurme P, Homil K, Lehtinen P, Turunen R, Vahlberg T, Vuorinen T, Camargo CA Jr, Gern JE, Jartti T. Efficacy of inhaled salbutamol with and without prednisolone for first acute rhinovirus-induced wheezing episode. Clin Exp Allergy. 2021 Sep;51(9):1121-1132. doi: 10.1111/cea.13960. Epub 2021 Jun 19.
Reference Type
DERIVED
Koistinen A, Lukkarinen M, Turunen R, Vuorinen T, Vahlberg T, Camargo CA Jr, Gern J, Ruuskanen O, Jartti T. Prednisolone for the first rhinovirus-induced wheezing and 4-year asthma risk: A randomized trial. Pediatr Allergy Immunol. 2017 Sep;28(6):557-563. doi: 10.1111/pai.12749. Epub 2017 Aug 6.
Reference Type
DERIVED
Lukkarinen M, Koistinen A, Turunen R, Lehtinen P, Vuorinen T, Jartti T. Rhinovirus-induced first wheezing episode predicts atopic but not nonatopic asthma at school age. J Allergy Clin Immunol. 2017 Oct;140(4):988-995. doi: 10.1016/j.jaci.2016.12.991. Epub 2017 Mar 25.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
http://vinku.utu.fi/
home page of the VINKU study group
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VINKU2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Systems Pharmacology Approach to Uncontrolled Pediatric Asthma
NCT04865575
COMPLETED
Inflammatory and Immune Profiles During a Severe Exacerbation in Preschool Asthmatic Children (<5 Years)
NCT03960359
ACTIVE_NOT_RECRUITING
The Effect of Montelukast Treatment in Wheezy Infants
NCT00934713
COMPLETED
PHASE4
A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)
NCT01502371
COMPLETED
PHASE2
Oral Prednisolone Dosing in Children Hospitalized With Asthma
NCT00257933
COMPLETED
PHASE4
Montelukast for Early Life Wheezing
NCT00115297
COMPLETED
PHASE2/PHASE3
Quality of Life in Asthmatic Children at School Age
NCT01475916
UNKNOWN
NA
Randomised Controlled Trial of a Multi-faceted Community-based Intervention to Improve Asthma in Children
NCT00238888
COMPLETED
PHASE4
Instrument Utility for Suspected Asthma (0000-042)(COMPLETED)
NCT00211575
COMPLETED
NA
Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing
NCT03889743
RECRUITING
PHASE4
Asthma in Children
NCT01286532
COMPLETED
Montelukast in Children With Wheezing
NCT00775697
UNKNOWN
PHASE4
Longitudinal Assessment of Children With Severe Asthma and Severe Pre-school Wheeze
NCT01982162
COMPLETED
Individualized Therapy For Asthma in Toddlers
NCT01606306
COMPLETED
PHASE3
Early Diagnosis of Asthma in Young Children
NCT00422747
COMPLETED
NA
Correlation of Particulate Matter and Heme Oxygenase-1 Protein Activity in Asthmatic Children by Induced Sputum Analysis.
NCT00969670
UNKNOWN
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
NCT05857930
ACTIVE_NOT_RECRUITING
PHASE2
Azithromycin Treatment of Hospitalized Children With Asthmatic Symptoms
NCT05028153
RECRUITING
PHASE2
Interventions to Improve Asthma Management/Prevention at School
NCT00005736
COMPLETED
Predicting Factors for Asthma Remission in Children
NCT02531503
COMPLETED
Preventing Asthma in High Risk Kids
NCT02570984
ACTIVE_NOT_RECRUITING
PHASE2
Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma
NCT01227070
COMPLETED
Effects of Montelukast in Children With Asthma
NCT00675285
COMPLETED
PHASE3
Albuterol HFA MDI in Pediatric Participants With Asthma
NCT00577655
COMPLETED
PHASE3